renaissance capital, page-37

Yes, it seems an awful lot for the current program given that total research and development costs last year were under $5m, they are half way through the trial, and they have @ $25m in cash left. Either there has been a complete blow-out of costs due to having to manufacture additional compound, or they are planning more than one trial. They have mentioned an additional $3m towards scale up of manufacturing though and I would assume that includes compound for the current trial.

There are only another 8 patients left to dose, so an explanation of why this is costing so much would be appreciated.